Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
09 Sep 2017 ESMO 2017 Media Alert: Hot Topic at ESMO 2017: Session Focuses on Adjuvant Chemotherapy Duration in Colon Cancer
09 Sep 2017 ESMO 2017 Press Release: Osimertinib Improves Progression-free Survival in Patients with EGFR Mutated Lung Cancer Lung and other thoracic tumours
08 Sep 2017 ESMO 2017: Combined Nivolumab and Radiotherapy ± Temozolomide Is Safe in Patients With Newly Diagnosed Glioblastoma Central nervous system malignancies - Cancer Immunology and Immunotherapy
08 Sep 2017 ESMO 2017: PD-L1 as a Prognostic Factor in Patients with Glioblastoma Central nervous system malignancies - Pathology/Molecular biology
08 Sep 2017 ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Patients with Platinum Sensitive Ovarian Cancer Maintan QoL During Maintenance Niraparib Therapy Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Germline Mutations in DNA Repair Genes Lowers Survival in mCRPC Genitourinary cancers - Translational research
08 Sep 2017 ESMO 2017: Significant Clinical Activity Demonstrated with 177Lu-PSMA617 in mCRPC Genitourinary cancers
08 Sep 2017 ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Combined Letrozole plus Palbociclib is not Better than Chemotherapy as Neoadjuvant Treatment in Luminal Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Combined Taselisib and Letrozole Improves Response in Postmenopausal Women with ER-positive, HER-negative Early Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy Gastrointestinal cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017 Press Release: DNA Sequencing Could Open Up New Drug Indications for Patients with Rare Cancers Translational research
08 Sep 2017 ESMO 2017 Press Release: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments Genitourinary cancers